Gout, the most common form of inflammatory arthritis, requires precise clinical management guided by the 2020 American College of Rheumatology recommendations. Dr. Lori Albert, a rheumatologist at the University of Toronto, emphasizes that hyperuricemia alone does not warrant treatment; rather, urate-lowering therapy is indicated for patients exhibiting tophi, radiographic joint damage, or recurrent flares. Allopurinol serves as the first-line intervention, safe for use even in patients with chronic kidney disease, with titration aimed at a target serum urate level of 350 micromoles per liter. Therapy initiation can safely occur during an acute flare when paired with anti-inflammatory prophylaxis. Beyond pharmacotherapy, patients should prioritize lifestyle modifications, specifically reducing high-fructose corn syrup and purine intake, alongside weight management to lower the risk of future attacks and mitigate long-term joint damage.
Sign in to continue reading, translating and more.
Open full episode in Podwise